Company intelligence / Profile preview
AriBio
Seongnam-si, South Koreaaribio.com ↗
- Ownership
- Private
- Employees
- ~113
- Development stage
- Phase 3
01
Overview
Currently conducting POLARIS-AD Phase 3 study for Alzheimer's disease using AR1001, a PDE5 inhibitor that inhibits neuron apoptosis, promotes neurogenesis, increases neuroplasticity and stimulates autophagy activity to remove toxic proteins
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (PDE5 inhibitor)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Fujirebio Diagnostics, Inc. (for biomarker development)
Beyond the preview
Go deeper on AriBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AriBio.